A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD)

Registry ID

SOBI.PEGCET-101

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Start date

2023-06-07

Completion date

2024-01-22

Last update

2022-05-17

Conditions

• COLD AGGLUTININ DISEASE

Related clinical trials

• A MULTICENTER, PHASE 1B, OPEN LABEL, NONRANDOMIZED, SINGLE DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY AND ACTIVITY OF BIVV020 IN ADULTS WITH COLD AGGLUTININ DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION

View on source registry